Pages

▼

Friday, 31 August 2018

ERC1671 vaccine randomized phase 2 trial results

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts.

Median overall survival (OS) of patients treated with ERC1671 plus bevacizumab was 12 months. In the placebo plus bevacizumab group, median OS was 7.5 months. The maximal CD4+ T-lymphocyte count correlated with OS in the ERC1671 but not in the placebo group.

CONCLUSION:

The addition of ERC1671/GM-CSF/cyclophosphamide to bevacizumab resulted in a clinically meaningful survival benefit with minimal additional toxicity.
at

3 comments:

  1. Stephen W1 September 2018 at 11:17

    This report is based on only the first 9 patients in the trial (out of a total of around 84) who were unblinded at progression.

    ReplyDelete
  2. Unknown4 September 2018 at 09:16

    This was one of two trials that Cancer Commons suggested for my husband. Looks like there is also availability under compassionate use.

    ReplyDelete
  3. Esther2 October 2018 at 22:32

    My husband was on this trial but now is at his second recurrence. The trial was thus unblinded but there hasn’t been significant improvement in scans and he recently developed left side weakness. I’m hoping it’s inflammation from recent radiation to the new area along with inflammation from vaccines. We are looking to pursue mdna55.

    ReplyDelete